ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RX Biosyent Inc

11.30
0.10 (0.89%)
05 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Biosyent Inc TSXV:RX TSX Venture Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 0.89% 11.30 11.25 11.45 11.30 11.25 11.26 1,253 21:59:03

BioSyent Schedules Q4 and Full Year 2020 Earnings Release for March 17, 2021

11/03/2021 1:00pm

GlobeNewswire Inc.


Biosyent (TSXV:RX)
Historical Stock Chart


From Nov 2019 to Nov 2024

Click Here for more Biosyent Charts.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2020 on Wednesday, March 17, 2021. A presentation on the Company’s fourth quarter and full year 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 12,740,775 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web: www.biosyent.com

1 Year Biosyent Chart

1 Year Biosyent Chart

1 Month Biosyent Chart

1 Month Biosyent Chart

Your Recent History

Delayed Upgrade Clock